BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27324442)

  • 1. ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.
    Ylä-Herttuala S
    Mol Ther; 2016 Jun; 24(6):1013-1014. PubMed ID: 27324442
    [No Abstract]   [Full Text] [Related]  

  • 2. Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID.
    Schimmer J; Breazzano S
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):57-61. PubMed ID: 27267267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
    Montiel-Equihua CA; Thrasher AJ; Gaspar HB
    Curr Gene Ther; 2012 Feb; 12(1):57-65. PubMed ID: 22348551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
    Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for ADA-SCID, the first marketing approval of an
    Aiuti A; Roncarolo MG; Naldini L
    EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Promising Option for ADA-SCID Patients.
    Am J Med Genet A; 2021 Nov; 185(11):3184-3185. PubMed ID: 34655170
    [No Abstract]   [Full Text] [Related]  

  • 7. EMA greenlights second gene therapy.
    Mullard A
    Nat Rev Drug Discov; 2016 May; 15(5):299. PubMed ID: 27139988
    [No Abstract]   [Full Text] [Related]  

  • 8. Gene therapy's out-of-body experience.
    Scott CT; DeFrancesco L
    Nat Biotechnol; 2016 Jun; 34(6):600-7. PubMed ID: 27281416
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
    Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
    Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising Results with Ex Vivo Lentiviral HSPC Gene Therapy in ADA-SCID.
    Am J Med Genet A; 2021 Aug; 185(8):2291-2292. PubMed ID: 34240545
    [No Abstract]   [Full Text] [Related]  

  • 11. A Journey in the Development of Gene Therapy for Inherited Disorders of the Bone Marrow.
    Kohn D; Wilson JM
    Hum Gene Ther Clin Dev; 2015 Dec; 26(4):203-7. PubMed ID: 26684443
    [No Abstract]   [Full Text] [Related]  

  • 12. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
    Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
    Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
    Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
    J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
    Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
    Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.
    Cicalese MP; Ferrua F; Castagnaro L; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Roncarolo MG; Aiuti A
    Mol Ther; 2018 Mar; 26(3):917-931. PubMed ID: 29433935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
    Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
    Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
    Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ADA gene expression and transduction efficiency in ADA/SCID patients undergoing gene therapy.
    Carlucci F; Tabucchi A; Aiuti A; Rosi F; Floccari F; Pagani R; Marinello E
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1245-8. PubMed ID: 15571238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
    Silver JN; Flotte TR
    Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.